Top Tweets for #DMARDS
ICYMI: “The aim of this review is to compare existing guideline recommendations for the use of #DMARDs in pregnancy and reproductive health for patients with #rheumatic disease.” @ACRheum #Rheumatology
Read more: https://t.co/v6J1mwzQ2D
#Autoimmune #progressive #pulmonary #fibrosis
Large Spanish registry
❎more mortality if not on #DMARDs
?underRx of proven #Rx with #antifibrotics
Median survival post #dx #PPF 7.8 yrs
Can we do better?
#ABST POS0430
@RheumNow #EULAR2026
“#DMARDs are the only drugs that really interfere with the disease process, and must be initiated as soon as the diagnosis has been made,” - Dr. Josef Smolen @univienna.
https://t.co/N4m9unGchM
Rheumatoid arthritis isn’t just joint pain - it’s a treatable autoimmune disease.
Daily self-care + regular DMARDs = long-term joint preservation.
Don’t wait for deformities. Control inflammation early.
#RheumatoidArthritis #Rheumatology @docakx @IhabFathiSulima #DMARDs #Autoimmune #TreatToTarget #MedTwitter #MedEd
#Women with #spondyloarthritis (SpA) show markedly shorter persistence on first and second #biologic #DMARDs (bDMARDs) despite similar initiation timing, as demonstrated by real-world data from Spanish REGISPONSER/REGISPON-3 registry:
◦ Study population: 411 SpA patients (271 males, 140 females) followed for 17 years (REGISPONSER → REGISPON-3).
◦ bDMARD initiation: No significant sex difference in time to first bDMARD (from symptoms or diagnosis).
◦ Males showed significantly longer persistence (retention) on bDMARD therapy compared to females:
- First bDMARD: males 88 months vs females 48 months (p = 0.004)
- Second bDMARD: males 260 months vs females 133 months (p = 0.0007)
◦ Multivariable analyses (Cox proportional hazards models) revealed sex-specific predictors of bDMARD initiation.
◦ The main reason for discontinuation was inefficacy in both sexes, but adverse events were reported more frequently as a reason for stopping treatment in females.
These findings indicate that while the timing of starting bDMARDs is similar between males and females with SpA, women demonstrate significantly shorter persistence on biological treatments over the long-term follow-up.
*Moldovan DMM, Ladehesa-Pineda L, Puche-Larrubia MÁ et al. Sex-based differences in bDMARD initiation and persistence in spondyloarthritis: a 17-year follow-up study from the REGISPON-3 registry. Rheumatology (Oxford). Published online March 21, 2026.
🔗https://t.co/P2UVjRv2pP
The updated #EULAR recommendations for the management of #rheumatoid #arthritis (RA) with synthetic and biologic #DMARDs have just been published in Annals of Rheumatic Diseases.
These 2025 updated EULAR recommendations are the most concise version yet, further simplifying treatment. They incorporate the latest evidence on efficacy and safety of conventional synthetic, biologic, and targeted synthetic DMARDs, and are summarized in this graphic algorithm.
Key elements unchanged:
◦ Start with methotrexate + short-term glucocorticoids
◦ If this fails, switch to a biologic/ targeted synthetic DMARD
◦ Target remission or low disease activity at every stage
◦ Aim to reach the target within 6 months
Main updates involve fine-tuning:
◦ Initiation of and switching between biologic/ targeted synthetic DMARDs
◦ Management after achieving and sustaining the treatment target
📊 Algorithm of the 2025 EULAR RA management recommendations.
*Smolen JS, Edwards CJ, Konzett V, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. Published online March 13, 2026.
🔗https://t.co/dTWCt5sYmo
📢Join our Physician Webinar on DMARDs in IIM 🧪
🗓 22nd Sept | ⏰ 3PM Lisbon | 10AM EST | 7:30PM IST
🎙 Dr. Eduardo Dourado (Portugal) & Dr. Siddharth Jain (India)
🔗 Register now: [https://t.co/8fdoxyT6Vc]
#Myositis #DMARDs #Webinar #Rheumatology
![Myositis_India's tweet photo. 📢Join our Physician Webinar on DMARDs in IIM 🧪
🗓 22nd Sept | ⏰ 3PM Lisbon | 10AM EST | 7:30PM IST
🎙 Dr. Eduardo Dourado (Portugal) & Dr. Siddharth Jain (India)
🔗 Register now: [https://t.co/8fdoxyT6Vc]
#Myositis #DMARDs #Webinar #Rheumatology https://t.co/PoZmvmi3Ow](https://pbs.twimg.com/media/G08ptTkXUAAQU0j.jpg)
⚠️’Pencil in cup’ deformity -
highly suggestive of #PsoriaticArthritis
There are proliferative and erosive bone changes concurrently
#erosivedisease #PsA #IA #Biolgics #DMARDS #psoriasis
By @therheumreview
Post 11
Steroid-sparing strategy:
•Pair steroids with a plan to wean: DMARDs for IA (MTX, leflunomide, sulfasalazine); consider biologic/JAK when indicated
•In recurrent PMR relapses, consider steroid-sparing agents
#DMARDs #Biologics #Rheumatology
🔚
📚 Take-home
DMARDs are the cornerstone of modern rheumatology.
They turned a once-deforming disease into a manageable one — even one with hope for remission.
They don’t just treat symptoms.
They change the game.
#Rheumatology #RA #DMARDs #Autoimmunity #MedTwitter #PostGradMedicine
💊 DMARDs aren’t just painkillers—they modify the disease from the root!
Start early, stay consistent, and follow-up smart.
Autoimmune doesn’t have to mean unstoppable.
#Rheumatology #AutoimmuneDisease #DMARDs #PatientEducation #MedTwitter @IhabFathiSulima @DrAkhilX @nileshnolkha
#Metastatic #melanoma Rx w #DMARDs & #TNFi OK
>7.5mg/d #prednisone ⬆️risk of recurrence over time
@FloridaRheums #FSR2025
Dr Suarez-Almaroz
Comparative efficacy of #DMARDs for patients with #cardiac #sarcoidosis (US cohort, n = 3,441 patients, 601 cardiac sarcoidosis and 2,840 non-cardiac sarcoidosis)
◦ An initial choice of therapy (#methotrexate, #mycophenolate mofetil, #azathioprine) for patients with cardiac sarcoidosis was not associated with the risk of subsequent severe cardiac outcomes.
◦ Among patients without cardiac sarcoidosis, initial therapy was not associated with subsequent development of cardiac sarcoidosis.
◦ Methotrexate had a favorable safety profile with respect to risk of infection as compared to mycophenolate mofetil or azathioprine.
*Brooks L, Kivlin W, Mohananey D, Sabchyshyn V, Putman M. Comparative effectiveness of disease-modifying antirheumatic drugs for patients with cardiac sarcoidosis. Rheumatology (Oxford). 2025;64(6):3303-3308.
🔗https://t.co/7edRX0ZKar
📌 This very interesting new study from the Netherlands suggests that once biological #DMARDs are introduced, we may already be too deep into the game, making drug-free remission in #rheumatoidarthritis a distant dream.
https://t.co/w9WQSIFBm9
Summary of the 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs
#Spondyloarthritis #axSpA #AnkylosingSpondylitis #Biologics #DMARDs
*Zhao SS et al. Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs, Rheumatology (Oxford), 2025.
🔗https://t.co/9m2kQwRYMA
Check out the 2025 British Society for Rheumatology guideline on treating axial spondyloarthritis with biologic & targeted synthetic DMARDs.
#Rheumatology #AxialSpondyloarthritis #DMARDs #Biologics
The first meta-analysis comparing efficacy and safety profiles of #JAK inhibitor (JAKi) versus commonly adopted #biologic #DMARDs for treating children with nonsystemic forms of juvenile idiopathic #arthritis, including newly available secukinumab, did not reveal any statistically significant difference among these advanced treatment options in terms of both efficacy and safety outcomes. New in this study, comparisons between JAKi and biologic/conventional DMARDs control arms did not show a statistically significant difference.
*Li, Y., Huang, B., Andorf, S., Yue, X., Lovell, D.J. and Brunner, H.I. (2025), Comparative Effectiveness and Safety of the JAK Inhibitors and Biologic Disease-Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta-Analysis of Randomized Controlled Trials. ACR Open Rheumatology, 7: e11788.
🔗https://t.co/3ZItvvb61v
-BIOLOGICAL THERAPIES HAVE ANY EFFECT ON #NEUROPATHIC #PAIN IN #RHEUMATOID #ARTHRITIS?
-THE RELATED FACTORS? https://t.co/o01K0dpTxN
#dmards #treatment #target #eular @BunyaminKisacik @NeslihanGken7 @MuratTa12529659 @anarsiknotrofil @Janetbirdope @RheumNow @LastManStand85
Comparative efficacy of #DMARDs for patients with cardiac sarcoidosis (US cohort, n = 3,441 patients, 601 defined as #cardiac #sarcoidosis and 2,840 as non-cardiac sarcoidosis)
🔹An initial choice of therapy (#methotrexate, #mycophenolate mofetil, #azathioprine) for patients with cardiac sarcoidosis was not associated with the risk of subsequent severe cardiac outcomes.
🔹Among patients without cardiac sarcoidosis, initial therapy was not associated with subsequent development of cardiac sarcoidosis.
🔹Methotrexate had a favorable safety profile with respect to risk of infection as compared to mycophenolate mofetil or azathioprine.
*Brooks L, Kivlin W, Mohananey D, Sabchyshyn V, Putman M. Comparative effectiveness of disease modifying antirheumatic drugs for patients with cardiac sarcoidosis. Rheumatology (Oxford). Published online December 26, 2024.
🔗https://t.co/7edRX0ZKar
Seronegative and seropositive #rheumatoid #arthritis (RA) are probably different diseases and have different patterns of response to #biological #DMARDs (bDMARDs). In a recently published Italian study that assessed the real-world effectiveness of bDMARDs, seropositive RA patients exhibited similar 10-year survival rates for #abatacept, anti-#TNFα drugs, and #tocilizumab, whereas seronegative RA demonstrated a notably different pattern of bDMARDs survival: tocilizumab showed the highest survival rate (73.9%), followed by anti-TNFα (50.0%) and lastly abatacept (37.5%), with a statistically significant difference between tocilizumab and abatacept.
*Iannone F, Lopalco G, Cacciapaglia F, Venerito V, Perniola S, Fornaro M. Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis. Rheumatology (Oxford). 2024;63(12):3442-3448
🔗https://t.co/V7W0Of1aiV
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.7M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.7M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.7M followers
Taylor Swift
@taylorswift13
81.6M followers
Lady Gaga
@ladygaga
73.1M followers
Virat Kohli
@imvkohli
70M followers
Kim Kardashian
@kimkardashian
69.8M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.9M followers
Neymar Jr
@neymarjr
62.8M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.8M followers